# OnCo record rtog-9402 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/rtog-9402/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "rtog-9402", "NCT00002569" ;
  schema:name "RTOG 9402"@en ;
  schema:description "RTOG 9402 looked negative at first and then, with long follow-up, showed that adding PCV chemotherapy to radiotherapy doubles survival in oligodendrogliomas with 1p/19q co-deletion, from about seven to fourteen years."@en ;
  schema:url <https://onco.cc/trials/rtog-9402/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT00002569>, <https://doi.org/10.1200/JCO.2012.43.2674> ;
  onco:status "positive" ;
  onco:tag "radiation-wave4" ;
  onco:phase "3" ;
  schema:startDate "1994-07" ;
  onco:cancers <https://onco.cc/cancers/glioblastoma/>, <https://onco.cc/cancers/brain-tumours/>, <https://onco.cc/cancers/oligodendroglioma/> ;
  onco:technologies <https://onco.cc/technologies/imrt-igrt/> ;
  onco:drugs <https://onco.cc/drugs/lomustine/>, <https://onco.cc/drugs/vincristine/>, <https://onco.cc/drugs/procarbazine/> ;
  onco:companies <https://onco.cc/companies/nrg-oncology/> ;
  onco:terms <https://onco.cc/terms/chemoradiation/> .